In initial trials, severe adverse events were documented while testing an anti-CD28 agonist in healthy control patients (126), while early trials of Peresolimab in RA do not suggest the development of severe adverse events (61), and in cancer, agonistic antibodies targeting OX40 showed acceptable safety profiles (127). This evidence concerns the gene TNFRSF4 and rheumatoid arthritis.